Menveo Market 2026 expanding with immunization programs

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Large Is The Menveo Market Projected To Become By 2030 Based On Its 2026 Valuation?

Historical growth stemmed from the broadening of national immunization programs, past occurrences of meningococcal disease outbreaks, improvements in conjugate vaccine technology, enhanced public understanding of diseases preventable by vaccination, and global immunization efforts.

Anticipated expansion during the forecast period is fueled by escalating investments in vaccine innovation, a heightened focus on preventing outbreaks, the broadening of adult and adolescent immunization coverage, an uptick in demand for travel-related vaccinations, and the reinforcement of public health infrastructure. Additionally, significant trends anticipated during this period involve the increasing uptake of conjugate vaccines, an intensified focus on preventive immunization strategies, expanding demand for adolescent and travel vaccinations, the wider deployment of multivalent vaccine coverage, and a greater emphasis on public health readiness.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20153&type=smp

What Drivers Are Shaping The Future Growth Of The Menveo Market?

The increasing incidence of meningitis is projected to fuel the expansion of the menveo market in the coming years. Meningitis is an infection characterized by inflammation of the protective membranes surrounding the brain and spinal cord, commonly triggered by viral, bacterial, or fungal agents. The escalating prevalence of meningitis is primarily driven by factors such as enhanced global travel and weakened immune systems, both of which amplify the risk of disease transmission. Menveo contributes to public health initiatives by offering protection against various strains of Neisseria meningitidis, thereby enabling early prevention, curtailing disease dissemination, and lessening the impact of invasive meningococcal infections. For instance, in October 2025, the UK Health Security Agency, a UK-based government body, reported a total of 378 confirmed invasive meningococcal disease (IMD) cases during the 2024–25 period. Consequently, the rising prevalence of meningitis is a key factor driving the growth of the menveo market. Menveo Market Driver: Impact Of Global Healthcare Infrastructure Expansion On Market Growth

What Segment Groups Are Identified Within The Menveo Market?

The menveo market covered in this report is segmented –

1) By Type of Vaccine: Conjugate Vaccine, Combination Vaccine

2) By Indication: Meningococcal Disease Prevention, Routine Immunization, Outbreak Control, Travel Vaccination

3) By Age Group: Infants and Young Children, Adolescents, Adults, Older Adults

4) By End User: Hospitals, Vaccination Clinics, Travel Clinics, Academic And Research Institutions, Military And Government Facilities

What Trends Are Advancing Progress In The Menveo Market?

A significant development in the Menveo market is the creation of innovative vaccine formulations, such as single-vial, fully liquid preparations, designed to improve convenience, enhance stability, and simplify vaccine administration. These single-vial, fully liquid formulations refer to pharmaceutical products that are pre-mixed and packaged in a single vial, with the active ingredients already dissolved in liquid form, ready for use. For instance, in November 2024, GlaxoSmithKline (GSK) plc, a UK-based pharmaceutical industry company, secured approval from the European Commission (EC) for a new version of its meningococcal vaccine, Menveo, intended for active immunization against invasive meningococcal disease (IMD) caused by serogroups A, C, W, and Y. The vaccine is now authorized for use in children aged two years and older, adolescents, and adults. Key aspects of this approval for the vaccine include its licensing for active immunization within the European Union for children from two years of age, adolescents, and adults, featuring a new single-vial, fully liquid presentation that eliminates the need for reconstitution prior to administration.

Which Companies Hold Significant Positions In The Menveo Market?

Major companies operating in the menveo market are GlaxoSmithKline (GSK) Plc

Read the full menveo market report here:

https://www.thebusinessresearchcompany.com/report/menveo-global-market-report

Which Geographic Regions Are Influencing Demand In The Menveo Market?

North America was the largest region in the menveo market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the menveo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Menveo Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20153&type=smp

Browse Through More Reports Similar to the Global Menveo Market 2026, By The Business Research Company

Renewable Diesel Market Report 2026

https://www.thebusinessresearchcompany.com/report/renewable-diesel-global-market-report

Hypermarkets Market Report 2026

https://www.thebusinessresearchcompany.com/report/hypermarkets-global-market-report

Biopreservation Market Report 2026

https://www.thebusinessresearchcompany.com/report/biopreservation-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795